Matches in SemOpenAlex for { <https://semopenalex.org/work/W2749813512> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- W2749813512 endingPage "223" @default.
- W2749813512 startingPage "213" @default.
- W2749813512 abstract "espanolIntroduccion. La enfermedad fungica invasora (EFI) es una importante causa de morbimortalidad en pacientes hematologicos. La profilaxis antifungica (PAF) esta indicada en muchos episodios de este grupo de pacientes. El objetivo de este trabajo fue alcanzar un consenso sobre el abordaje profilactico de las EFI en el paciente hematologico con el fin de optimizar su manejo. Metodos. Un comite de expertos en hematologia y enfermedades infecciosas planteo un cuestionario de 79 items con aspectos controvertidos sobre la profilaxis antifungica en el paciente hematologico. El cuestionario fue evaluado en dos rondas por un panel de expertos siguiendo una metodologia Delphi modificada. Resultados. El cuestionario fue respondido por 44 expertos en hematologia y enfermedades infecciosas. Tras dos rondas de evaluacion se consensuaron 48 items en el acuerdo (60,7%) y 19 en el desacuerdo (24%) por lo que hubo consenso en 67 de los 79 items planteados (84,8%). Se consensuaron los perfiles de pacientes candidatos a profilaxis y se dilucidaron cuestiones relacionadas con indicaciones, mecanismos de accion, espectro de actividad, toxicidad e interacciones de los antifungicos. Se analizo particularmente la utilidad de micafungina como profilaxis de EFI. Se consensuo que micafungina es un antifungico a considerar en este contexto. Puede presentar ventajas sobre otros antifungicos por su seguridad y menor potencial de interacciones. Conclusiones. Se encontro un alto nivel de consenso en el manejo de la profilaxis de la EFI en el paciente hematologico. Este consenso ofrece indicaciones practicas sobre su manejo optimo y puede ayudar a determinar el perfil de los pacientes idoneos a recibir este tipo de intervencion. EnglishIntroduction. Invasive fungal disease (IFD) is an important cause of morbidity and mortality in haematological patients. Antifungal prophylaxis (AFP) is indicated for a number of clinical scenarios in this group of patients. The aim of this study was to reach a consensus on IFD prophylaxis in haematological patients in order to optimize their management. Methods. A committee of experts in haematology and infectious diseases compiled a survey of 79 items with controversial aspects about antifungal prophylaxis in haematological patients. The survey was evaluated in two rounds by a panel of experts following a modified Delphi methodology. Results. Forty-four experts in haematology and infectious diseases answered the survey. After two evaluation rounds, consensus was reached in 67 of the 79 items (84.8%), specifically 48 items were consensually agreed on (60.7%) and 19 were disagreed on (24.0%). Consensus was reached on prophylaxis candidates profiles and questions related to indications, mechanisms of action, spectrum of activity, toxicity and interactions of antifungal were elucidated. The usefulness of micafungin in IFD prophylaxis was particularly analysed. The consensus reached was that micafungin is an antifungal to be considered in this context as its safety profile and lower interaction potential may be advantageous. Conclusions. A broad consensus was found in the management of IFD prophylaxis in the haematological patient. This consensus provides practical indications about its optimal management and can help determine the profile of patients eligible for this type of intervention." @default.
- W2749813512 created "2017-08-31" @default.
- W2749813512 creator A5007057534 @default.
- W2749813512 creator A5007074198 @default.
- W2749813512 creator A5018653818 @default.
- W2749813512 creator A5047511054 @default.
- W2749813512 creator A5051826479 @default.
- W2749813512 creator A5061436383 @default.
- W2749813512 creator A5066183078 @default.
- W2749813512 creator A5070240359 @default.
- W2749813512 creator A5076211343 @default.
- W2749813512 creator A5086113423 @default.
- W2749813512 creator A5086359357 @default.
- W2749813512 date "2017-01-01" @default.
- W2749813512 modified "2023-09-26" @default.
- W2749813512 title "Posicionamiento y actitudes de manejo sobre la profilaxis antifúngica en el paciente hematológico (proyecto PROMIC)" @default.
- W2749813512 hasPublicationYear "2017" @default.
- W2749813512 type Work @default.
- W2749813512 sameAs 2749813512 @default.
- W2749813512 citedByCount "0" @default.
- W2749813512 crossrefType "journal-article" @default.
- W2749813512 hasAuthorship W2749813512A5007057534 @default.
- W2749813512 hasAuthorship W2749813512A5007074198 @default.
- W2749813512 hasAuthorship W2749813512A5018653818 @default.
- W2749813512 hasAuthorship W2749813512A5047511054 @default.
- W2749813512 hasAuthorship W2749813512A5051826479 @default.
- W2749813512 hasAuthorship W2749813512A5061436383 @default.
- W2749813512 hasAuthorship W2749813512A5066183078 @default.
- W2749813512 hasAuthorship W2749813512A5070240359 @default.
- W2749813512 hasAuthorship W2749813512A5076211343 @default.
- W2749813512 hasAuthorship W2749813512A5086113423 @default.
- W2749813512 hasAuthorship W2749813512A5086359357 @default.
- W2749813512 hasConcept C138885662 @default.
- W2749813512 hasConcept C15708023 @default.
- W2749813512 hasConcept C29456083 @default.
- W2749813512 hasConcept C71924100 @default.
- W2749813512 hasConceptScore W2749813512C138885662 @default.
- W2749813512 hasConceptScore W2749813512C15708023 @default.
- W2749813512 hasConceptScore W2749813512C29456083 @default.
- W2749813512 hasConceptScore W2749813512C71924100 @default.
- W2749813512 hasIssue "3" @default.
- W2749813512 hasLocation W27498135121 @default.
- W2749813512 hasOpenAccess W2749813512 @default.
- W2749813512 hasPrimaryLocation W27498135121 @default.
- W2749813512 hasVolume "30" @default.
- W2749813512 isParatext "false" @default.
- W2749813512 isRetracted "false" @default.
- W2749813512 magId "2749813512" @default.
- W2749813512 workType "article" @default.